Correvio Pharma Corp.
Lead Plaintiff Deadline: 02/10/2020
SUMMARY OF CASE:
A securities class action has been filed against Correvio Pharma Corp. (CORV) on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Correvio securities between October 23, 2018 through December 5, 2019. This case has been filed in the USDC – S.D.N.Y.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statementsand/or failed to disclosethat: (i) the data supporting the Resubmitted NDA for Brinavess did not minimizethe significant health and safety issuesobserved in connection with the drug’s original NDA; (ii) the foregoing substantially diminished the likelihood that the FDA would approve the Resubmitted NDA; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.